Related Experiment Video
Updated: Aug 16, 2026
Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
[Clinical application of ibudilast for elder patients with chronic subdural hematoma]
Hirotsugu Ohta1, Tetsuya Genmoto, Daisuke Akiba
1Department of Neurosurgery, Chikuhou Rosai Hospital, Fukuoka 820-0088, Japan.
Insights
Ibudilast effectively reduced chronic subdural hematoma (CSDH) volumes and prevented recurrence in patients. This platelet-activating factor receptor antagonist shows promise for CSDH management.
Area of Science:
- Neurosurgery
- Pharmacology
- Neurology
Background:
- Chronic subdural hematoma (CSH) is a significant neurosurgical condition.
- Recurrence of CSH poses a challenge in patient management.
- Platelet-activating factor (PAF) is implicated in inflammatory processes and fluid accumulation in CSH.
Observation:
- Ibudilast, a PAF receptor antagonist, was administered to patients diagnosed with CSH.
- Brain computed tomography (CT) scans were utilized to measure hematoma volumes.
- Measurements were taken approximately 1-2 months post-treatment initiation.
Findings:
- Patients treated with ibudilast exhibited significantly smaller remaining subdural hematoma volumes.
- No recurrence of chronic subdural hematoma was observed in the ibudilast treatment group.
- Ibudilast demonstrated a positive effect on CSH resolution.
Implications:
- Ibudilast may serve as a valuable therapeutic agent for preventing CSH recurrence.
- Further clinical trials are warranted to confirm the efficacy and safety of ibudilast in CSH.
- Targeting PAF receptors with ibudilast offers a novel therapeutic strategy for CSH.
Abstract:
Ibudilast, an antagonist of platelet-activating factor receptors, was administered to patients with chronic subdural hematoma (CSDH) to assess its effectiveness in preventing recurrence. The remaining volumes of subdural hematomas on brain computed tomography were measured approximately 1-2 months after using ibudilast. The hematomas were significantly smaller and there was no recurrence. Ibudilast administration may be useful in the prevention of recurrence of CSDH.
